Peripheral CD8+CD28- T cell level reflects tumor immunity and could predict anti- HER2 based therapy response in metastatic breast cancer

Huiping Li(Peking University), Yiqiang Liu(Peking University)
Research Square
April 25, 2022
10.21203/rs.3.rs-1571322/v1
Cited by 0

Related Papers

Inavolisib-Based Therapy in <i>PIK3CA</i> -Mutated Advanced Breast Cancer
|New England Journal of Medicine|2024|235
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
|Nature Communications|2018|106
Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A dependent Axis
|Journal of Experimental & Clinical Cancer Research|2020|91
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
|BMJ|2023|82
Persistence of peripheral CD8 + CD28− T cells indicates a favourable outcome and tumour immunity in first-line HER2-positive metastatic breast cancer
|British Journal of Cancer|2024|0